Mitral valve repair was linked to a significant improvement in long-term survival when treating infective endocarditis. Some patients are not good candidates for a repair procedure, however, making replacement the best possible option.

Howard Herrmann, MD,  MSCAI, Hospital of the University of Pennsylvania, and lead invesigator for the SMART trial, explains details on the 2-year data comparing the Evolut vs. Sapien 3 for TAVR in small annulus patients.

“Clear signs of an aortic dissection” were missed in the patient's imaging findings after he presented to the emergency room, according to the lawsuit. He was diagnosed with acute pericarditis at the time and sent home—and then died four days later.

Researchers explored five-year data from more than 1,800 patients with nonvalvular AFib who underwent LAAO with Abbott's Amulet or Boston Scientific's Watchman 2.5. 

Clinicians are asking the world's medical societies to come together and agree on one acronym for TAVR/TAVI to avoid unnecessary confusion going forward.

TAVR adoption in Africa has been relatively slow, but cardiologists throughout the continent have made considerable progress. New data does show that there is some work to be done before outcomes will rival what is seen in many other parts of the world.

TAVR is associated with a significantly lower risk of bioprosthetic valve dysfunction than SAVR, according to new data presented at CRT 2025 and simultaneously published in JACC. 

Researchers presented new two-year data from the SMART trial at CRT 2025 in Washington, D.C. Overall, self-expanding TAVR valves continue to show superior valve performance compared to balloon-expandable valves, and clinical outcomes remain comparable.